Faculty profile

Rajat Kumar

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Rajat Kumar

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
70 publications in the last five years, latest in 2026.
Senior (last) author on 8 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

114

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Allogenic Blood And Marrow Transplant Hematologic Malignancies Rehabilitation

Latest papers

Herpes Zoster Frequency and Adjuvanted Recombinant Zoster Vaccination after Allogeneic Hematopoietic Cell Transplantation.
Transplantation and cellular therapy · 2026
Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.
Transplantation and cellular therapy · 2026
The Effect of Smoking and Pre-Allogeneic Hematopoietic Cell Transplant Pulmonary Comorbidity on the Incidence of Lung Graft-Versus-Host Disease and Post-Transplant Outcomes.
Cancers · 2026

All 114 publications

Latest funding

A type 1 hybrid effectiveness-implementation trial of a longitudinal multidimensional rehabilitation program for patients undergoing allogeneic blood and marrow transplantation (CaRE-4-alloBMT)
CIHR · 2024 · Principal investigator
$638,776
Early discontinuation of antibiotics for unexplained febrile neutropenia: a pilot randomized controlled trial- EASE ANTIBIOTICS pilot trial
CIHR · 2023 · Co-investigator
$512,551
Myelodysplastic Syndromes (MDS) in Canada: A national prospective study of the epidemiology, quality of life and impact of co-morbidity/frailty on disease outcome
CIHR · 2011 · Co-investigator
$100,000

All 3 grants and awards

114 publications.

Herpes Zoster Frequency and Adjuvanted Recombinant Zoster Vaccination after Allogeneic Hematopoietic Cell Transplantation.

Hall VG, Chiarello C, Remberger M, Kumar D, Pasic I, Kim DDH, Kumar R, Viswabandya A, Michelis FV, Law A, Gerbitz A, Humar S, Lam W, Novitzky-Basso I, Mattsson J

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2025.10.028 PMID: 41167523

Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.

Chiarello C, Singhabahu S, Remberger M, Chen C, Moya TA, Al-Shaibani E, Gerbitz A, Kim DDH, Kumar R, Lam W, Law AD, Lipton JH, Michelis FV, Novitzky-Basso I, Viswabandya A, Mattsson J, Pasic I

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2025.10.002 PMID: 41062023

The Effect of Smoking and Pre-Allogeneic Hematopoietic Cell Transplant Pulmonary Comorbidity on the Incidence of Lung Graft-Versus-Host Disease and Post-Transplant Outcomes.

Reda E, Kawari M, Pereira MP, Remberger M, Lau A, Law AD, Kumar R, Novitzky-Basso I, Lam W, Pasic I, Gerbitz A, Viswabandya A, Kim DD, Lipton JH, Mattsson J, Michelis FV

Cancers2026

DOI: 10.3390/cancers18020295 PMID: 41595214

HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study.

Salas MQ, Alfaro Moya T, Pasic I, Baile González M, Gómez MA, Fox L, Pérez Artigas MDM, Santamaría A, Quintela González MDC, Sánchez Salinas A, Salmerón Camacho JM, Illana Álvaro V, Abdallahi-Lefdil Z, Navascues JC, Pardo L, Fernández-Luis S, Vega Suárez LP, Villar S, Beorlegui-Murillo P, Esquirol A, Izquierdo García I, Mussetti A, Lavilla E, Lopez-Marín J, Filaferro S, Balsalobre P, Bento L, Law A, Viswabandya A, Michelis FV, Mattsson J, Alibhai S, Rovira M, Wang Kim DD, Sureda A, Kumar R

EClinicalMedicine2026Senior author

DOI: 10.1016/j.eclinm.2025.103753 PMID: 41567713

CMV reactivation post allogeneic stem cell transplantation decreases relapse risk and survival, and increases NRM - a single center analysis.

Stavi V, Chen C, Novitzky-Basso I, Remberger M, Law A, Gerbitz A, Viswabandya A, Kim DDH, Michelis FV, Pasic I, Kumar R, Lam W, Mattsson J, Lipton JH

Leukemia & lymphoma2026

DOI: 10.1080/10428194.2026.2668034 PMID: 42132052

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

Desai N, Rodriguez-Rodriguez S, Chen C, Al-Shaibani E, Alfaro Moya T, Novitzky-Basso I, Pasic I, Michelis FV, Viswabandya A, Kim DDH, Kumar R, Mattsson J, Law AD

JCO oncology practice2026

DOI: 10.1200/op-25-01308 PMID: 42372210

Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Rodriguez-Rodriguez S, Salas MQ, Desai N, Al-Shaibani E, Novitzky-Basso I, Pasic I, Viswabandya A, Michelis FV, Mattsson J, Kim DDH, Kumar R, Moya TA

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.01.026 PMID: 41571188

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Pasic I, Novitzky-Basso I, Viswabandya A, Kim DD, Kumar R, Lipton JH, Mattsson J, Michelis FV

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.05.018 PMID: 42142626

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.

Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A

British journal of haematology2026

DOI: 10.1111/bjh.70380 PMID: 41747740

Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.

Rodriguez-Rodriguez S, Chiarello C, Desai N, Remberger M, Chen C, Al-Shaibani E, Alfaro Moya T, Law AD, Pasic I, Viswabandya A, Michelis FV, Kim DDH, Kumar R, Mattsson J, Novitzky-Basso I

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.03.015 PMID: 41839367

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2024

Subject: Prospective PhD student: Allogenic Blood And Marrow Transplant Dear Professor Kumar, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Herpes Zoster Frequency and Adjuvanted Recombinant Zoster Vaccination after Allogeneic Hematopoietic Cell Transplantation." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "A type 1 hybrid effectiveness-implementation trial of a longitudinal multidimensional rehabilitation program for patients undergoing allogeneic blood and marrow transplantation (CaRE-4-alloBMT)" (2024), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Rajat Kumar

Research

Latest papers

Latest funding

Herpes Zoster Frequency and Adjuvanted Recombinant Zoster Vaccination after Allogeneic Hematopoietic Cell Transplantation.

Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.

The Effect of Smoking and Pre-Allogeneic Hematopoietic Cell Transplant Pulmonary Comorbidity on the Incidence of Lung Graft-Versus-Host Disease and Post-Transplant Outcomes.

HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study.

CMV reactivation post allogeneic stem cell transplantation decreases relapse risk and survival, and increases NRM - a single center analysis.

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.

Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.

A type 1 hybrid effectiveness-implementation trial of a longitudinal multidimensional rehabilitation program for patients undergoing allogeneic blood and marrow transplantation (CaRE-4-alloBMT)

Early discontinuation of antibiotics for unexplained febrile neutropenia: a pilot randomized controlled trial- EASE ANTIBIOTICS pilot trial

Myelodysplastic Syndromes (MDS) in Canada: A national prospective study of the epidemiology, quality of life and impact of co-morbidity/frailty on disease outcome

Frequent collaborators

Jonas Mattsson

Tommy Alfaro Moya

Steven Chan

Mark Minden

Tracy Stockley

Aaron Schimmer

Shabbir Alibhai

Zhaolei Zhang

David Langelier

Deepali Kumar

Shahid Husain

Tony Mazzulli

Christine Cserti-Gazdewich

Adam Smith

Lisa Avery

Michael Kennah

Hyewon Lee

David Allan

Lesley Moody

Vathany Kulasingam

Samantha Mayo

Phedias Diamandis

Alejandro Berlin

Breffni Hannon

Christopher Bredeson

Kylie Lepic

James Kennedy

Irwin Ronald Walker

Gelareh Zadeh

Shereen Ezzat